The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Pre-transplant salvage options: bringing conventional versus novel combinations to practice 

Jun 6, 2019

During ASCO 2019, Chicago, US, Alison J Moskowitz, Memorial Sloan Kettering Cancer Center, New York, US, spoke to the Lymphoma Hub about pre-transplant salvage options: bringing conventional versus novel combinations to practice.

Dr. Moskowitz explains that the general approach for a patient that has relapsed or refactor disease after their frontline treatment for Hodgkin lymphoma (HL) is to give some kind of second-line therapy followed by consolidation with an autologous stem cell transplant and the choice of treatment is dependant upon the institution treating the patient. These treatments may include traditional therapies such as ICE, chemotherapy, or DHAP based regimes. However, now that there are newer regimes available for HL such as rituximab and checkpoint inhibitors these are now being considered when treating second-line therapy patients.

Pre-transplant salvage options: bringing conventional versus novel combinations to practice